ATE278414T1 - Therapien zur behandlung von akutem nierenversagen - Google Patents

Therapien zur behandlung von akutem nierenversagen

Info

Publication number: ATE278414T1
Authority: AT; Austria
Prior art keywords: treatment; therapies; kidney failure; acute kidney; risk
Prior art date: 1997-05-05

Application number

AT98919715T

Other languages

English (en)

Inventor

Kuber T Sampath

Charles M Cohen

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-05

Filing date

1998-05-05

Publication date

2004-10-15

1998-05-05 Application filed by Curis Inc filed Critical Curis Inc

2004-10-15 Application granted granted Critical

2004-10-15 Publication of ATE278414T1 publication Critical patent/ATE278414T1/de

Links

208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
208000033626 Renal failure acute Diseases 0.000 title abstract 2
201000011040 acute kidney failure Diseases 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 3
102000004169 proteins and genes Human genes 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
208000012998 acute renal failure Diseases 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
230000005779 cell damage Effects 0.000 abstract 1
208000037887 cell injury Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
210000000440 neutrophil Anatomy 0.000 abstract 1
230000002188 osteogenic effect Effects 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
230000000451 tissue damage Effects 0.000 abstract 1
231100000827 tissue damage Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT98919715T 1997-05-05 1998-05-05 Therapien zur behandlung von akutem nierenversagen ATE278414T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4561997P	1997-05-05	1997-05-05
PCT/US1998/003197 WO1998050060A1 (en)	1997-05-05	1998-05-05	Therapies for acute renal failure

Publications (1)

Publication Number	Publication Date
ATE278414T1 true ATE278414T1 (de)	2004-10-15

Family

ID=21938961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98919715T ATE278414T1 (de)	1997-05-05	1998-05-05	Therapien zur behandlung von akutem nierenversagen

Country Status (11)

Country	Link
US (2)	US20100105621A1 (de)
EP (1)	EP0980252B1 (de)
JP (2)	JP5033276B2 (de)
AT (1)	ATE278414T1 (de)
AU (1)	AU743510B2 (de)
CA (1)	CA2289123A1 (de)
DE (1)	DE69826854T2 (de)
DK (1)	DK0980252T3 (de)
ES (1)	ES2226125T3 (de)
PT (1)	PT980252E (de)
WO (1)	WO1998050060A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7612046B2 (en)	2000-01-31	2009-11-03	Uwe Waldemar Rothenpieler	Method for treating kidney disorders
CA2398310C (en) *	2000-01-31	2015-11-24	Uwe Waldemar Rothenpieler	Methods for treating kidney disorders with pax2
WO2003000257A1 (en) *	2001-06-26	2003-01-03	Takeda Chemical Industries, Ltd.	TGF-ß SUPERFAMILY PRODUCTION/SECRETION PROMOTER
WO2004019876A2 (en) *	2002-08-28	2004-03-11	Curis, Inc.	Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
RU2282899C2 (ru) *	2004-01-09	2006-08-27	ГОУ ВПО Омская Государственная Медицинская Академия	Способ моделирования инфекции мочевой системы
EP1951751B1 (de) *	2005-11-14	2017-11-01	Merial, Inc.	Gentherapie bei nierenversagen
EP2047862B9 (de) *	2006-07-21	2013-04-10	Chugai Seiyaku Kabushiki Kaisha	Mittel zur behandlung von nierenerkrankungen
US8979797B2 (en) *	2010-12-16	2015-03-17	Ams Research Corporation	High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9359417B2 (en)	2013-01-25	2016-06-07	Warsaw Orthopedic, Inc.	Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8956829B2 (en)	2013-01-25	2015-02-17	Warsaw Orthopedic, Inc.	Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en)	2013-01-25	2015-06-09	Warsaw Orthopedic, Inc.	Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en)	2013-01-25	2015-10-27	Warsaw Orthopedic, Inc.	Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en)	2013-01-25	2015-02-03	Warsaw Orthopedic, Inc.	Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
CN106102761A (zh)	2014-02-07	2016-11-09	宫崎彻	用于肾疾病的预防或治疗剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1156741B (it)	1978-05-15	1987-02-04	Sigma Tau Ind Farmaceuti	Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en)	1979-07-20	1982-08-03	Morinaga Milk Industry Co., Ltd.	Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) *	1985-11-21	1986-12-09	American Hospital Supply Corporation	Patient controlled analgesia conversion
IL83003A (en)	1986-07-01	1995-07-31	Genetics Inst	Osteoinductive factors
US5013649A (en) *	1986-07-01	1991-05-07	Genetics Institute, Inc.	DNA sequences encoding osteoinductive products
US5266683A (en) *	1988-04-08	1993-11-30	Stryker Corporation	Osteogenic proteins
US5011691A (en) *	1988-08-15	1991-04-30	Stryker Corporation	Osteogenic devices
US5045452A (en) *	1988-09-02	1991-09-03	Brigham And Women's Hospital	Method for evaluating nephrotoxicity
ATE162223T1 (de)	1989-03-28	1998-01-15	Genetics Inst	Osteoinduktive zusammensetzungen
CA2082941A1 (en)	1990-05-16	1991-11-17	Rodney M. Hewick	Bone and cartilage inductive proteins
JPH0426624A (ja)	1990-05-18	1992-01-29	Tsumura & Co	慢性腎不全改善剤
ATE146076T1 (de)	1990-06-22	1996-12-15	Du Pont	Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US7056882B2 (en) *	1991-03-11	2006-06-06	Curis, Inc.	Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6077823A (en) *	1991-03-11	2000-06-20	Creative Biomolecules, Inc.	Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) *	1991-03-11	2010-05-18	Curis, Inc.	Protein-induced morphogenesis
US5849686A (en) *	1991-03-11	1998-12-15	Creative Biomolecules, Inc.	Morphogen-induced liver regeneration
DK0575555T3 (da)	1991-03-11	2001-11-05	Curis Inc	Proteininduceret morfogenese
US6194376B1 (en) *	1991-03-11	2001-02-27	Creative Biomolecules, Inc.	Method for modulating inflammatory response comprising administering morphogen
US6287816B1 (en)	1991-06-25	2001-09-11	Genetics Institute, Inc.	BMP-9 compositions
EP1637156A1 (de) *	1991-08-30	2006-03-22	Curis, Inc.	Systemische Gabe osteogener Proteine zur Behandlung metabolischer Knochenkrankheiten
ATE197611T1 (de)	1991-08-30	2000-12-15	Creative Biomolecules Inc	Screeningverfahren von morphogenischen proteinen
DE69231062T3 (de) *	1991-08-30	2004-07-29	Creative Biomolecules, Inc., Hopkinton	Morphogen-induzierte Modulation von entzündlichen Antworten
US6120760A (en) *	1992-02-12	2000-09-19	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung	Growth/differentiation factors of the TGF-β family
EP0661933B1 (de)	1992-07-31	1998-04-22	Creative Biomolecules, Inc.	Mit morphogen angereicherte nahrungszusammenstellung
AU681594B2 (en) *	1992-07-31	1997-09-04	Stryker Corporation	Morphogen-induced nerve regeneration and repair
WO1994003600A1 (en)	1992-07-31	1994-02-17	Creative Biomolecules, Inc.	Morphogenic protein soluble complex and composition thereof
CA2144514C (en)	1992-09-16	2002-03-26	Thangavel Kuberasampath	Morphogen-induced liver regeneration
WO1994010203A2 (en)	1992-11-03	1994-05-11	Creative Biomolecules, Inc.	Op-3-induced morphogenesis
CA2157387C (en)	1993-03-04	1998-12-15	David C. Rueger	Method and compositions for recombinant osteogenic protein production
US5631159A (en)	1993-09-22	1997-05-20	Creative Biomolecules, Inc.	Lipid-modified serum free media
US5585237A (en)	1993-10-25	1996-12-17	Creative Biomolecules, Inc.	Methods and compositions for high protein production from recombinant DNA
AU690941B2 (en) *	1993-11-15	1998-05-07	Celtrix Pharmaceuticals, Inc.	Method of treating renal disease by administering IGF-I and IGFBP-3
US5525621A (en) *	1994-05-20	1996-06-11	Cytos Pharmaceuticals Llc	Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) *	1995-07-31	1998-02-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
ATE493141T1 (de) *	1996-03-22	2011-01-15	Stryker Corp	Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US5820589A (en) *	1996-04-30	1998-10-13	Medtronic, Inc.	Implantable non-invasive rate-adjustable pump
US6498142B1 (en)	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
US5879908A (en) *	1997-04-30	1999-03-09	Smithkline Beecham Corporation	CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en)	1998-05-29	2006-12-12	Curis, Inc.	Methods for evaluating tissue morphogenesis and activity

1998
- 1998-05-05 AU AU72443/98A patent/AU743510B2/en not_active Ceased
- 1998-05-05 AT AT98919715T patent/ATE278414T1/de active
- 1998-05-05 ES ES98919715T patent/ES2226125T3/es not_active Expired - Lifetime
- 1998-05-05 DE DE69826854T patent/DE69826854T2/de not_active Expired - Lifetime
- 1998-05-05 PT PT98919715T patent/PT980252E/pt unknown
- 1998-05-05 CA CA002289123A patent/CA2289123A1/en not_active Abandoned
- 1998-05-05 EP EP98919715A patent/EP0980252B1/de not_active Expired - Lifetime
- 1998-05-05 WO PCT/US1998/003197 patent/WO1998050060A1/en not_active Ceased
- 1998-05-05 JP JP54804898A patent/JP5033276B2/ja not_active Expired - Fee Related
- 1998-05-05 DK DK98919715T patent/DK0980252T3/da active
2009
- 2009-08-11 US US12/583,013 patent/US20100105621A1/en not_active Abandoned
- 2009-09-11 JP JP2009211128A patent/JP2009286802A/ja not_active Withdrawn
2011
- 2011-04-04 US US13/079,161 patent/US8748378B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69826854T2 (de)	2006-02-02
DE69826854D1 (de)	2004-11-11
EP0980252B1 (de)	2004-10-06
US20100105621A1 (en)	2010-04-29
JP2001523264A (ja)	2001-11-20
ES2226125T3 (es)	2005-03-16
JP5033276B2 (ja)	2012-09-26
CA2289123A1 (en)	1998-11-12
AU743510B2 (en)	2002-01-24
US8748378B2 (en)	2014-06-10
WO1998050060A1 (en)	1998-11-12
JP2009286802A (ja)	2009-12-10
EP0980252A1 (de)	2000-02-23
US20110257093A1 (en)	2011-10-20
PT980252E (pt)	2005-01-31
AU7244398A (en)	1998-11-27
DK0980252T3 (da)	2005-01-31

Legal Events

Date

Code

Title

Description

2005-05-15

UEP

Publication of translation of european patent specification

Ref document number: 0980252

Country of ref document: EP

2011-05-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
ATE277629T1 (de)	2004-10-15	Morphogenische behandlung des chronischen nierenversagens
DE69826854D1 (de)	2004-11-11	Therapien zur behandlung von akutem nierenversagen
EA199801044A1 (ru)	1999-04-29	Модуляторы регенерации тканей
DK0429570T3 (da)	1998-04-27	Osteoinducerende præparater
WO1998033509A3 (en)	1999-03-11	Useful properties of human lactoferrin and variants thereof
DE69736974D1 (de)	2007-01-04	System zur filtration von medizinischen und biologischen flüssigkeiten
DE69827192D1 (de)	2004-12-02	Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DE69703689D1 (de)	2001-01-18	Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DK52089D0 (da)	1989-02-03	Middel til behandling af nyresygdomme
ATE273031T1 (de)	2004-08-15	Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
ATE433461T1 (de)	2009-06-15	Rana pipiens proteine und deren verwendung in der behandlung von tumoren
SE8902532D0 (sv)	1989-07-14	Bestaemning av plasmaproteiner
DE69633393D1 (de)	2004-10-21	Mitteln zur behandlung von auto-immun krankheiten
EP0960117A4 (de)	2000-06-14	ZU FIBROBLASTEN-WACHSTUMSFAKTOR HOMOLOGE FAKTOREN (FHFs) UND VERFAHREN DER ANWENDUNG
DE69916488D1 (de)	2004-05-19	Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
TR199900596T2 (xx)	1999-06-21	Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
EP1185283A4 (de)	2003-07-02	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
ATA113492A (de)	1994-08-15	Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
ATE238796T1 (de)	2003-05-15	Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
IT1292798B1 (it)	1999-02-11	Sistema sterile e procedimento di filtraggio di liquidi biologici o medicali, in particolare di sangue o componenti del sangue.
FI952170L (fi)	1995-11-07	Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
NO945031D0 (no)	1994-12-23	Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
DE69829995D1 (de)	2005-06-02	Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69821227D1 (de)	2004-02-26	Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE59805246D1 (de)	2002-09-26	Tissue-faktor zur beeinflussung von gefässbildung